Blog - Clinical Trials

Chief Medical Officer Ann Ginsberg offers highlights from our clinical work in 2016.

On September 3, 2015, Aeras hosted the 2015 Fall meeting of the Biomarkers and Correlates Working Group (BCWG) in Rockville, Maryland. Tuberculosis (TB) experts from around the world attended to discuss and make recommendations for the TB vaccine community regarding studies needed to better define biomarkers or correlates for risk of TB infection or disease, protection induced by vaccination, and endpoints for clinical trials.

A recent media symposium in South Africa, organized by Aeras, IAVI, AVAC, HVTN and CAPRISA, provided training and cleared up misconceptions about clinical trials for local journalists.

Professor Helen McShane is the lead author on a study funded in part by Aeras that was published in Lancet Respiratory Medicine in February. Dr. McShane sat down with Aeras to discuss how what was learned from this study and how it helps advance the field of TB vaccine research.

​Clinical trials are one of the most important stages in vaccine research and development. And while much of this research takes place in clinics and laboratories, none of it would be possible without the participation and support of the people in the surrounding communities.